Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Route 206 And Province Line Road
Princeton, NJ 08543Phone+1 732-500-2958- Is this information wrong?
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2010
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2008
- Rutgers Robert Wood Johnson Medical SchoolClass of 2005
Publications & Presentations
PubMed
- 14 citationsEvolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.John C O'Donnell, T Kim Le, Radu Dobrin, Mitch Higashi, Ashley Pereira, Samuel Wagner, Arvin Yang, Mathias Hukkelhoven> ;Future Oncology. 2021 Jan 1
- 47 citationsA Blueprint to Advance Colorectal Cancer Immunotherapies.Dung T. Le, Vanessa M Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur Nathan Brodsky, Emily Chan, Dustin A. Deming, Lui...> ;Cancer Immunology Research. 2017 Nov 1
- 2038 citationsNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phas...Jeffrey S. Weber, Sandra P. D'Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher...> ;The Lancet. Oncology. 2015 Apr 1
- Join now to see all
Press Mentions
- Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. As Senior Vice President and Chief Medical OfficerNovember 30th, 2020
- Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (Nivolumab) and Yervoy (Ipilimumab)September 28th, 2019
- Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data ShowsNovember 27th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: